The DOI matches its Crossref record; 119 of the 119 references it cites were found in a registry or an index.
Rho kinase, a promising drug target for neurological disorders
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Axonal transection in the lesions of multiple sclerosis
Trapp, B. D., Peterson, J., Ransohoff, R. M., Rudick, R., Mörk, S., & Bö, L. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801293380502 · Cited by 4,029
Specificity and mechanism of action of some commonly used protein kinase inhibitors
DAVIES, S. P., REDDY, H., CAIVANO, M., & COHEN, P. (2000) · Biochemical Journal · doi:10.1042/bj3510095 · Cited by 3,132
Regulation of Myosin Phosphatase by Rho and Rho-Associated Kinase (Rho-Kinase)
Kimura, K., Ito, M., Amano, M., Chihara, K., Fukata, Y., Nakafuku, M., Yamamori, B., Feng, J., Nakano, T., Okawa, K., et al. (1996) · Science · doi:10.1126/science.273.5272.245 · Cited by 2,884
Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension
Uehata, M., Ishizaki, T., Satoh, H., Ono, T., Kawahara, T., Morishita, T., Tamakawa, H., Yamagami, K., Inui, J., Maekawa, M., et al. (1997) · Nature · doi:10.1038/40187 · Cited by 2,859
Rho GTPases and their effector proteins
BISHOP, A. L., & HALL, A. (2000) · Biochemical Journal · doi:10.1042/bj3480241 · Cited by 2,575
Rho GTPases and signaling networks
Van Aelst, L., & D’Souza-Schorey, C. (1997) · Genes & Development · doi:10.1101/gad.11.18.2295 · Cited by 2,358
SOMLYO, A. P., & SOMLYO, A. V. (2003) · Physiological Reviews · doi:10.1152/physrev.00023.2003 · Cited by 1,991
ROCKs: multifunctional kinases in cell behaviour
Riento, K., & Ridley, A. J. (2003) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1128 · Cited by 1,941
McDonald, J. W., & Sadowsky, C. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07603-1 · Cited by 1,799
GEF means go: turning on RHO GTPases with guanine nucleotide-exchange factors
Rossman, K. L., Der, C. J., & Sondek, J. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1587 · Cited by 1,697
Cited by
Kinase-targeted cancer therapies: progress, challenges and future directions
Bhullar, K. S., Lagarón, N. O., McGowan, E. M., Parmar, I., Jha, A., Hubbard, B. P., & Rupasinghe, H. P. V. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0804-2 · Cited by 1,245
Therapeutic interventions after spinal cord injury
Thuret, S., Moon, L. D. F., & Gage, F. H. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1955 · Cited by 1,012
Rho‐kinase/ROCK: A key regulator of the cytoskeleton and cell polarity
Amano, M., Nakayama, M., & Kaibuchi, K. (2010) · Cytoskeleton · doi:10.1002/cm.20472 · Cited by 994
Anti-Inflammatory Effects of Statins: Clinical Evidence and Basic Mechanisms
Jain, M. K., & Ridker, P. M. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1901 · Cited by 915
Paul, S., & Candelario-Jalil, E. (2021) · Experimental Neurology · doi:10.1016/j.expneurol.2020.113518 · Cited by 748
GTP‐binding proteins of the Rho/Rac family: regulation, effectors and functions in vivo
Bustelo, X. R., Sauzeau, V., & Berenjeno, I. M. (2007) · BioEssays · doi:10.1002/bies.20558 · Cited by 634
Hypertension and Cerebrovascular Dysfunction
Iadecola, C., & Davisson, R. L. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.03.010 · Cited by 557
Rho Kinases in Cardiovascular Physiology and Pathophysiology
Loirand, G., Guérin, P., & Pacaud, P. (2006) · Circulation Research · doi:10.1161/01.res.0000201960.04223.3c · Cited by 547
Liao, J. J.-L. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm0608107 · Cited by 507
Zhou, Y., Huang, X., Hecker, L., Kurundkar, D., Kurundkar, A., Liu, H., Jin, T.-H., Desai, L., Bernard, K., & Thannickal, V. J. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66700 · Cited by 455
Liao, J. K., Seto, M., & Noma, K. (2007) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e318070d1bd · Cited by 401
The dendritic tree and brain disorders
Kulkarni, V. A., & Firestein, B. L. (2012) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2012.03.005 · Cited by 390
Rho Kinase (ROCK) Inhibitors and Their Therapeutic Potential
Feng, Y., LoGrasso, P. V., Defert, O., & Li, R. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00683 · Cited by 378
Physiological role of ROCKs in the cardiovascular system
Noma, K., Oyama, N., & Liao, J. K. (2006) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00459.2005 · Cited by 371
The role of amyloid β peptide 42 in Alzheimer's disease
Findeis, M. A. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.06.006 · Cited by 324
Role of lysophosphatidic acid and its receptors in health and disease: novel therapeutic strategies
Geraldo, L. H. M., Spohr, T. C. L. D. S., Amaral, R. F. D., Fonseca, A. C. C. D., Garcia, C., Mendes, F. D. A., Freitas, C., dosSantos, M. F., & Lima, F. R. S. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00367-5 · Cited by 313
Can regenerating axons recapitulate developmental guidance during recovery from spinal cord injury?
Harel, N. Y., & Strittmatter, S. M. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1957 · Cited by 300
Targeting protein kinases in central nervous system disorders
Chico, L. K., Van Eldik, L. J., & Watterson, D. M. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2999 · Cited by 298
RGMa inhibition promotes axonal growth and recovery after spinal cord injury
Hata, K., Fujitani, M., Yasuda, Y., Doya, H., Saito, T., Yamagishi, S., Mueller, B. K., & Yamashita, T. (2006) · The Journal of Cell Biology · doi:10.1083/jcb.200508143 · Cited by 289
Self-citationAxon growth inhibition by RhoA/ROCK in the central nervous system
Fujita, Y., & Yamashita, T. (2014) · Frontiers in Neuroscience · doi:10.3389/fnins.2014.00338 · Cited by 269
Rho Kinase Inhibitors as a Novel Treatment for Glaucoma and Ocular Hypertension
Tanna, A. P., & Johnson, M. (2018) · Ophthalmology · doi:10.1016/j.ophtha.2018.04.040 · Cited by 257
Rho kinase in the regulation of cell death and survival
Shi, J., & Wei, L. (2007) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-007-0009-7 · Cited by 254
ROCK inhibition in models of neurodegeneration and its potential for clinical translation
Koch, J. C., Tatenhorst, L., Roser, A.-E., Saal, K.-A., Tönges, L., & Lingor, P. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.03.008 · Cited by 239
Lingor, P., Teusch, N., Schwarz, K., Mueller, R., Mack, H., Bähr, M., & Mueller, B. K. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04756.x · Cited by 214
Self-citationROCK2 is a major regulator of axonal degeneration, neuronal death and axonal regeneration in the CNS
Koch, J. C., Tönges, L., Barski, E., Michel, U., Bähr, M., & Lingor, P. (2014) · Cell Death & Disease · doi:10.1038/cddis.2014.191 · Cited by 197
Tonges, L., Frank, T., Tatenhorst, L., Saal, K. A., Koch, J. C., Szego, E. M., Bahr, M., Weishaupt, J. H., & Lingor, P. (2012) · Brain · doi:10.1093/brain/aws254 · Cited by 176
Rho-kinase: Regulation, (dys)function, and inhibition
Amin, E., Dubey, B. N., Zhang, S.-C., Gremer, L., Dvorsky, R., Moll, J. M., Taha, M. S., Nagel-Steger, L., Piekorz, R. P., Somlyo, A. V., et al. (2013) · bchm · doi:10.1515/hsz-2013-0181 · Cited by 176
Phosphorylation of profilin by ROCK1 regulates polyglutamine aggregation
Shao, J., Welch, W. J., DiProspero, N. A., & Diamond, M. I. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.00079-08 · Cited by 171
Fasudil attenuates aggregation of α-synuclein in models of Parkinson’s disease
Tatenhorst, L., Eckermann, K., Dambeck, V., Fonseca-Ornelas, L., Walle, H., Lopes da Fonseca, T., Koch, J. C., Becker, S., Tönges, L., Bähr, M., et al. (2016) · Acta Neuropathologica Communications · doi:10.1186/s40478-016-0310-y · Cited by 158
Basheer, N., Smolek, T., Hassan, I., Liu, F., Iqbal, K., Zilka, N., & Novak, P. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02113-z · Cited by 159
Advances in small molecules promoting neurotrophic function
PRICE, R., MILNE, S., SHARKEY, J., & MATSUOKA, N. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.03.005 · Cited by 148
Barcia, C., Ros, C. M., Annese, V., Carrillo-de Sauvage, M. A., Ros-Bernal, F., Gómez, A., Yuste, J. E., Campuzano, C. M., de Pablos, V., Fernandez-Villalba, E., et al. (2012) · Scientific Reports · doi:10.1038/srep00809 · Cited by 150
Tönges, L., Günther, R., Suhr, M., Jansen, J., Balck, A., Saal, K., Barski, E., Nientied, T., Götz, A. A., Koch, J., et al. (2014) · Glia · doi:10.1002/glia.22601 · Cited by 121
“…of Gram-negative bacteria, was chosen as a stimulant because it signals through a complex of CD14 and Toll-like receptor (TLR) 4 (Hanisch, 2013a, 2013b; Regen et al., 2011) and has been shown to be crucially involved in microglia-mediated MN damage in ALS (Nguyen et al., 2004; Zhao et al., 2010).”
BackgroundSelf-citationVillar-Cheda, B., Dominguez-Meijide, A., Joglar, B., Rodriguez-Perez, A. I., Guerra, M. J., & Labandeira-Garcia, J. L. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.04.010 · Cited by 104
Role of RhoA/ROCK signaling in Alzheimer’s disease
Cai, R., Wang, Y., Huang, Z., Zou, Q., Pu, Y., Yu, C., & Cai, Z. (2021) · Behavioural Brain Research · doi:10.1016/j.bbr.2021.113481 · Cited by 96
Socodato, R., Portugal, C. C., Canedo, T., Rodrigues, A., Almeida, T. O., Henriques, J. F., Vaz, S. H., Magalhães, J., Silva, C. M., Baptista, F. I., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107796 · Cited by 94
Rho GTPases in Intellectual Disability: From Genetics to Therapeutic Opportunities
Zamboni, V., Jones, R., Umbach, A., Ammoni, A., Passafaro, M., Hirsch, E., & Merlo, G. R. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19061821 · Cited by 83
Ding, J., Li, Q., Wang, X., Sun, C., Lu, C., & Xiao, B. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06876.x · Cited by 79
Roser, A.-E., Tönges, L., & Lingor, P. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00094 · Cited by 77
Borrajo, A., Rodriguez-Perez, A. I., Villar-Cheda, B., Guerra, M. J., & Labandeira-Garcia, J. L. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.05.021 · Cited by 75
Gopalakrishnan, S. M., Teusch, N., Imhof, C., Bakker, M. H. M., Schurdak, M., Burns, D. J., & Warrior, U. (2008) · Journal of Neuroscience Research · doi:10.1002/jnr.21671 · Cited by 62
Self-citationAhmed, L. A., Darwish, H. A., Abdelsalam, R. M., & Amin, H. A. (2016) · Molecular Neurobiology · doi:10.1007/s12035-015-9303-2 · Cited by 55
Rho/ROCK Pathway and Noncoding RNAs: Implications in Ischemic Stroke and Spinal Cord Injury
Kimura, T., Horikoshi, Y., Kuriyagawa, C., & Niiyama, Y. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111573 · Cited by 55
Rho Kinase and Dopaminergic Degeneration: A Promising Therapeutic Target for Parkinson’s Disease
Labandeira-Garcia, J. L., Rodríguez-Perez, A. I., Villar-Cheda, B., Borrajo, A., Dominguez-Meijide, A., & Guerra, M. J. (2015) · The Neuroscientist · doi:10.1177/1073858414554954 · Cited by 54
Pharmacological Modulators of Small GTPases of Rho Family in Neurodegenerative Diseases
Guiler, W., Koehler, A., Boykin, C., & Lu, Q. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.661612 · Cited by 51
Lau, C. L., Perreau, V. M., Chen, M. J., Cate, H. S., Merlo, D., Cheung, N. S., O'Shea, R. D., & Beart, P. M. (2012) · Journal of Cellular Physiology · doi:10.1002/jcp.22838 · Cited by 49
“Our own work suggests an interdependent relationship between EAAT function and astrocytic phenotype (O’Shea et al., 2006; Zagami et al., 2009; Lau et al., 2010), so the up-regulation of EAAT2 as found in both the microarray and qRT-PCR studies was of great interest.”
BackgroundMethodInfluentialRegulation of Microglial Phagocytosis by RhoA/ROCK-Inhibiting Drugs
Scheiblich, H., & Bicker, G. (2017) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-016-0379-7 · Cited by 44
“…axonal recovery after spinal cord injury and as a therapeutic avenue for the treatment of major neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, and multiple sclerosis (Mueller et al. 2005; Tönges et al. 2011; Hensel et al. 2015).”
BackgroundInfluentialZhang, X., Ye, P., Wang, D., Liu, Y., Cao, L., Wang, Y., Xu, Y., & Zhu, C. (2019) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-019-00668-6 · Cited by 40
Cotargeting among microRNAs in the brain
Cherone, J. M., Jorgji, V., & Burge, C. B. (2019) · Genome Research · doi:10.1101/gr.249201.119 · Cited by 40
Huang, C.-H., Cheng, J.-C., Chen, J.-C., & Tseng, C.-P. (2007) · Cellular Signalling · doi:10.1016/j.cellsig.2007.01.019 · Cited by 29
Therapeutic effect of Rho kinase inhibitor FSD‑C10 in a mouse model of Alzheimer's disease
Gu, Q., Yu, J., Wu, H., Li, Y., Liu, C.-Y., Feng, L., Zhang, G., Xiao, B., & Ma, C. (2018) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2018.6701 · Cited by 27
Zhang, L., Ma, Q., Yang, W., Qi, X., Yao, Z., Liu, Y., Liang, L., Wang, X., Ma, C., Huang, L., et al. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.10.023 · Cited by 15
Metadata
- Authors
- Mueller, B. K., Mack, H., & Teusch, N.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2005-05
- Volume
- 4
- Issue
- 5
- Pages
- 387-398
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2019619408
- Cited by
- 608
- References
- 119
- FWCI
- 1.80
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.